

# ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of newly diagnosed large cell non-Hodgkin's lymphoma

## Incidence

- Large Cell Lymphoma constitutes 30–58% of non-Hodgkin's lymphoma series. The crude incidence in the European Union is 3–4/100 000 per year. The incidence increases with age from 0.3/100 000 per year (35–39 y) to 26.6/100 000 per year (80–84 y).

## Diagnosis

- Diagnosis should almost always be based on a surgical specimen/excisional lymph node biopsy providing enough material for fresh frozen and formalin-fixed samples. To ensure adequate quality, immediate processing by an experienced pathology institute has to be guaranteed.
- Fine needle aspirations or core biopsies may be appropriate as the only diagnostic test in the rare patients requiring emergency treatment or those not suitable for curative therapy.
- The histological report should give the diagnosis according to the WHO classification with use of CD20 immunohistochemistry.

## Staging and risk assessment

- Patients amenable to curative therapy should have at least a chest X-ray and a CT-scan of the abdomen, as well as a bone marrow aspirate and biopsy. A diagnostic spinal tap directly combined with a first prophylactic instillation of cytarabine or methotrexate shall be considered in high-risk patients [patients with more than two adverse parameters according to international prognostic index (IPI)] with e.g. involvement of bone marrow, testis, the spine, or the base of the skull [V, D].
- A complete blood count, routine blood chemistry including LDH and uric acid as well as a screening test for HIV and hepatitis B and C are required. Protein electrophoresis is recommended for B-cell lymphomas.
- The staging is given according to the Ann Arbor system with mentioning of bulky disease [III, A]. For prognostic purposes, the IPI should be established [III, A].

## Treatment plan

- A multidisciplinary treatment planning is required:  
*Treatment with curative intent:* CHOP-treatment combined with rituximab given every 21 days for usually 8 cycles is

the current standard for CD20+ large-cell non-Hodgkin's lymphoma of all stages [II, A]. In T-cell lymphoma, CHOP remains the standard. Shortening the interval between CHOP cycles to two weeks with growth factor support may be considered [II, B].

- High-dose chemotherapy with stem cell transplantation in poor risk patients remains experimental.
- Consolidation by radiotherapy to sites of bulky disease has not proven its benefit [III, C].
- Dose reductions due to hematological toxicity should be avoided and febrile neutropenia justifies prophylactic use of hematopoietic growth factors in patients treated with curative intent.

## Response evaluation

- Adequate radiological tests should be done after 2 to 4 cycles and after the last cycle of CHOP or CHOP + radiotherapy, and whenever there are doubts regarding adequate response.
- An initially pathologic bone marrow aspirate/biopsy or spinal tap should be repeated at the end of treatment.
- Patients with incomplete or lacking response should be evaluated for early salvage regimens.

## Follow-up

- History and physical examination every 3 months for 2 years, every 6 months for 3 more years, and then once a year with attention to development of secondary tumors [V, D]. High-risk patients still with curative options, such as high-dose chemotherapy with stem cell support, may mandate more frequent controls.
- Blood count and LDH at 3, 6, 12, and 24 months, then only as needed for evaluation of suspicious symptoms or clinical findings in those patients suitable for further therapy [V, D].
- Evaluation of thyroid dysfunction (TSH) in patients with irradiation to the neck at 1, 2, and at least at 5 years [III, A].
- After having received chest irradiation at premenopausal age, especially at an age below 25 years, women should be screened for secondary breast cancers clinically [III, A] and, after the age of 40–50 years, by mammography [III, C].
- Minimal adequate radiological examinations at 6, 12, and 24 months after end of treatment, by CT scan when indicated by site of disease [V, D].

## Note

Levels of Evidence [*I–V*] and Grades of Recommendation [*A–D*] as used by the American Society of Clinical Oncology are given in square brackets. Statements without grading were considered justified standard clinical practice by the experts and the ESMO faculty.

## Literature

1. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. *Blood* 1994; 84: 1361–1392.
2. Smithers DW. Summary of papers delivered at the Conference on Staging in Hodgkin's Disease (Ann Arbor). *Cancer Res* 1971; 31: 1869–1870.
3. Shipp M, Harrington D, Anderson J et al. A predictive model for aggressive non-Hodgkin's lymphoma. *N Engl J Med* 1993; 329: 987–994.
4. Cheson BD, Horning SJ, Coiffier B. Report of an international workshop to standardize response criteria for Non-Hodgkin's lymphomas. *J Clin Oncol* 1999; 17: 1244–1253.
5. Fisher RI, Gaynor ER, Dahlborg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. *N Engl J Med* 1993; 328: 1002–1006.
6. Miller TP, Dahlborg S, Cassady JR et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. *N Engl J Med* 1998; 339: 21–26.
7. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. *N Engl J Med* 2002; 346: 235–242.
8. Pfreundschuh M, Trumper L, Kloess M et al. German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. *Blood* 2004; 104: 634–641.
9. Pfreundschuh MG, Trumper L, Ma D et al. Randomized intergroup trial of first line treatment for patients ≤ 60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab—early stopping after the first interim analysis. *J Clin Oncol* 2004; 22(14S): (Abstr. 6500).

Coordinating authors for the ESMO Guidelines Task Force: L. M. Jost<sup>1</sup>, O. Kloeke<sup>2</sup> & R. A. Stahel<sup>3</sup>

<sup>1</sup>Invited author and member of the task force, Oncology, Kantonsspital, CH-4101 Bruderholz/BL, Switzerland; <sup>2</sup>Assigned task force member, Elisabeth Krankenhaus GmbH, Abt. Onkologie/Hämatologie, Röntgenstrasse 10, 45661 Recklinghausen, Germany; <sup>3</sup>Assigned task force member, Division of Oncology, University Hospital, Rämistrasse 100, CH-8091 Zürich, Switzerland

Approved by the ESMO Guidelines Task Force: February 2002, last update December 2004.

*Correspondence to:*  
ESMO Guidelines Task Force  
ESMO Head Office  
Via La Santa 7  
CH-6962 Lugano  
Switzerland